These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 37114781)
41. Novel phytochemical-antibiotic conjugates as multitarget inhibitors of Pseudomononas aeruginosa GyrB/ParE and DHFR. Jayaraman P; Sakharkar KR; Lim C; Siddiqi MI; Dhillon SK; Sakharkar MK Drug Des Devel Ther; 2013; 7():449-75. PubMed ID: 23818757 [TBL] [Abstract][Full Text] [Related]
42. Drug efficacy of novel 3-O-methoxy-4-halo disubstituted 5,7-dimethoxy chromans; evaluated via DNA gyrase inhibition, bacterial cell wall lesion and antibacterial prospective. Ponnusamy T; Alagumuthu M; Thamaraiselvi S Bioorg Med Chem; 2018 Jul; 26(12):3438-3452. PubMed ID: 29803359 [TBL] [Abstract][Full Text] [Related]
43. Design, synthesis, molecular modeling, and antimicrobial potential of novel 3-[(1H-pyrazol-3-yl)imino]indolin-2-one derivatives as DNA gyrase inhibitors. Alzahrani AY; Ammar YA; Salem MA; Abu-Elghait M; Ragab A Arch Pharm (Weinheim); 2022 Jan; 355(1):e2100266. PubMed ID: 34747519 [TBL] [Abstract][Full Text] [Related]
45. Identification of promising DNA GyrB inhibitors for Tuberculosis using pharmacophore-based virtual screening, molecular docking and molecular dynamics studies. Islam MA; Pillay TS Chem Biol Drug Des; 2017 Aug; 90(2):282-296. PubMed ID: 28109130 [TBL] [Abstract][Full Text] [Related]
46. Design, synthesis, antibacterial evaluation, and computational studies of hybrid oxothiazolidin-1,2,4-triazole scaffolds. Pathak P; Novak J; Shukla PK; Grishina M; Potemkin V; Verma A Arch Pharm (Weinheim); 2021 Jun; 354(6):e2000473. PubMed ID: 33656194 [TBL] [Abstract][Full Text] [Related]
47. Investigating the molecular mechanism of staphylococcal DNA gyrase inhibitors: A combined ligand-based and structure-based resources pipeline. Durdagi S; Tahir Ul Qamar M; Salmas RE; Tariq Q; Anwar F; Ashfaq UA J Mol Graph Model; 2018 Oct; 85():122-129. PubMed ID: 30176384 [TBL] [Abstract][Full Text] [Related]
48. Development and radiosterilization of new hydrazono-quinoline hybrids as DNA gyrase and topoisomerase IV inhibitors: Antimicrobial and hemolytic activities against uropathogenic isolates with molecular docking study. Ammar YA; Micky JA; Aboul-Magd DS; Abd El-Hafez SMA; Hessein SA; Ali AM; Ragab A Chem Biol Drug Des; 2023 Feb; 101(2):245-270. PubMed ID: 36305722 [TBL] [Abstract][Full Text] [Related]
49. Design, Synthesis, Kinetic Analysis and Pharmacophore-Directed Discovery of 3-Ethylaniline Hybrid Imino-Thiazolidinone as Potential Inhibitor of Carbonic Anhydrase II: An Emerging Biological Target for Treatment of Cancer. Ahmed A; Aziz M; Ejaz SA; Channar PA; Saeed A; Zargar S; Wani TA; Hamad A; Abbas Q; Raza H; Kim SJ Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36421710 [TBL] [Abstract][Full Text] [Related]
50. Molecular Docking Study of Active Diazenyl Scaffolds as Inhibitors of Essential Targets Towards Antimicrobial Drug Discovery. Kaur H; Gahlawat S; Singh J; Narasimhan B Curr Drug Targets; 2019; 20(15):1587-1602. PubMed ID: 31215386 [TBL] [Abstract][Full Text] [Related]
51. 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine. Chaudhari HK; Pahelkar A Infect Disord Drug Targets; 2019; 19(2):145-166. PubMed ID: 30324898 [TBL] [Abstract][Full Text] [Related]
52. Discovery of new Gyrase β inhibitors via structure based modeling. Al-Nadaf AH; Salah SA; Taha MO Comput Biol Chem; 2018 Jun; 74():263-272. PubMed ID: 29679863 [TBL] [Abstract][Full Text] [Related]
53. Design of novel quinoline-aminopiperidine derivatives as Wang J; Zhao C; Tu J; Yang H; Zhang X; Lv W; Zhai H J Biomol Struct Dyn; 2019 Jul; 37(11):2913-2925. PubMed ID: 30044186 [TBL] [Abstract][Full Text] [Related]
54. In silico designing of domain B selective gyrase inhibitors for effective treatment of resistant tuberculosis. Kashyap A; Singh PK; Silakari O Tuberculosis (Edinb); 2018 Sep; 112():83-88. PubMed ID: 30205973 [TBL] [Abstract][Full Text] [Related]
55. Mycobacterial DNA gyrB inhibitors: Ligand based pharmacophore modelling and in vitro enzyme inhibition studies. Saxena S; Renuka J; Jeankumar VU; Yogeeswari P; Sriram D Curr Top Med Chem; 2014; 14(17):1990-2005. PubMed ID: 25262795 [TBL] [Abstract][Full Text] [Related]
56. Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2 Musoev A; Numonov S; You Z; Gao H Molecules; 2019 Aug; 24(16):. PubMed ID: 31394858 [TBL] [Abstract][Full Text] [Related]
57. Discovery of Novel Mycobacterial DNA Gyrase B Inhibitors: In Silico and In Vitro Biological Evaluation. Saxena S; Renuka J; Yogeeswari P; Sriram D Mol Inform; 2014 Sep; 33(9):597-609. PubMed ID: 27486079 [TBL] [Abstract][Full Text] [Related]
58. Discovery of novel oxoindolin derivatives as atypical dual inhibitors for DNA Gyrase and FabH. Yang YS; Su MM; Xu JF; Liu QX; Bai LF; Hu XW; Zhu HL Bioorg Chem; 2019 Dec; 93():103309. PubMed ID: 31585266 [TBL] [Abstract][Full Text] [Related]
59. Synthesis, Antibacterial Activity, Interaction with Nucleobase and Molecular Docking Studies of 4-Formylbenzoic Acid Based Thiazoles. Laczkowski KZ; Biernasiuk A; Baranowska-Laczkowska A; Misiura K; Malm A; Plech T; Paneth A Med Chem; 2016; 12(6):553-62. PubMed ID: 26833073 [TBL] [Abstract][Full Text] [Related]
60. Synthesis, Docking Studies, and In Vitro Evaluation of Some Novel Thienopyridines and Fused Thienopyridine-Quinolines as Antibacterial Agents and DNA Gyrase Inhibitors. Mohi El-Deen EM; Abd El-Meguid EA; Hasabelnaby S; Karam EA; Nossier ES Molecules; 2019 Oct; 24(20):. PubMed ID: 31658631 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]